H. Lundbeck A/S
HLUN-A
Rang in aandelen
#2989
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aandeelprijs
$7.41
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$6.17B
Verandering (1 dag)
3.44%
Verandering (1 jaar)
34.71%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Categorie
Healthcare
Dividendgeschiedenis van H. Lundbeck A/S (HLUN-A)
H. Lundbeck A/S (aandelsymbool: HLUN-A) heeft in totaal 4 dividenduitkeringen gedaan.
De som van alle dividenden (aangepast voor aandelensplitsingen) is: $3.38
Dividendrendement (TTM): 0.0242
De som van alle dividenden (aangepast voor aandelensplitsingen) is: $3.38
Dividendrendement (TTM): 0.0242
Dividendbetalingen voor H. Lundbeck A/S (HLUN-A) van 2023 tot 2026
Jaarlijkse dividendbetalingen
| Jaar | Dividend (aangepast voor aandelensplitsingen) | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.15 | 21.05% |
| 2025 | $0.95 | 35.71% |
| 2024 | $0.7 | 20.69% |
| 2023 | $0.58 | 0.00% |
Lijst van alle dividendbetalingen
| Jaar | Dividend | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.15 | 21.05% |
| 2025 | $0.95 | 35.71% |
| 2024 | $0.7 | 20.69% |
| 2023 | $0.58 | 0.00% |
Dividendbetalingen voor vergelijkbare bedrijven of concurrenten
| Bedrijf | Aantal dividendbetalingen | Land |
|---|---|---|
| 23.00% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
